C12N 2710/24121
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2710/24121 (Viruses as such) appears on 81 US grants and 128 published applications in this corpus.
Search patents in C12N- Granted patents
- 81
- Published applications
- 128
- Assignees
- 60
- Inventors
- 224
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 3 |
| 2004 | 1 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 2 |
| 2007 | 1 | 0 |
| 2008 | 3 | 1 |
| 2009 | 0 | 6 |
| 2010 | 0 | 1 |
| 2011 | 4 | 4 |
| 2012 | 4 | 6 |
| 2013 | 0 | 3 |
| 2014 | 2 | 1 |
| 2015 | 5 | 4 |
| 2016 | 1 | 9 |
| 2017 | 6 | 5 |
| 2018 | 6 | 3 |
| 2019 | 1 | 11 |
| 2020 | 9 | 14 |
| 2021 | 3 | 6 |
| 2022 | 8 | 18 |
| 2023 | 8 | 15 |
| 2024 | 4 | 3 |
| 2025 | 7 | 4 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- Oncolytic vaccinia virus21 Jul 2026US 12,686,856 B2KM Biologics Co., Ltd.
- Oncolytic vaccinia virus26 May 2026US 12,637,663 B2KM Biologics Co., Ltd.
- Synthetic chimeric vaccinia virus20 Jan 2026US 12,529,036 B2Tonix Pharma Limited
- Immuno-oncolytic therapies6 Jan 2026US 12,514,888 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors16 Jul 2026US 2026/0199414 A1Turnstone Biologics Corp.
- Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof21 May 2026US 2026/0137773 A1ViroMissile, Inc.
- Synthetic chimeric poxviruses21 May 2026US 2026/0139233 A1Tonix Pharma Limited
- Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof9 Apr 2026US 2026/0097116 A1ViroMissile, Inc.
- Recombinant virus expressing interleukin-1212 Mar 2026US 2026/0071233 A1AstraZeneca AB
Most cited
By later US patents
- Modified vaccinia ankara virus variant99US 6,761,893 B2Bavarian Nordic A/S · 2004
- Modified Vaccinia Ankara virus variant43US 6,913,752 B2Bavarian Nordic A/S · 2005
- Modified vaccinia virus strains for use in diagnostic and therapeutic methods40US 8,052,968 B2Genelux Corporation · 2011
- Modified vaccinia ankara virus variant32US 7,189,536 B2Bavarian Nordic A/S · 2007
- Modified Vaccinia Ankara virus variant29US 7,384,644 B2Bavarian Nordic A/S · 2008